Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| no clinical added value |
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO). |
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
X8sPJgHV8ZCzwnr4
